Presence of CSE1L protein in urine of patients with urinary bladder urothelial carcinomas

2012 ◽  
Vol 27 (3) ◽  
pp. 280-284 ◽  
Author(s):  
Cheng-Jeng Tai ◽  
Ching-Fong Liao ◽  
Tzu-Cheng Su ◽  
Ko-Hung Shen ◽  
Chun-Chao Chang ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urinary Bladder ◽  
Tumor Cells ◽  
Chromosome Segregation ◽  
Immunohistochemical Analysis ◽  
High Expression ◽  
Healthy Controls ◽  
Urothelial Carcinomas ◽  
Normal Bladder

The chromosome segregation 1-like (CSE1L) protein is highly expressed in most cancers and has been shown to be secreted by tumor cells. We studied the presence of CSE1L in the urine of patients with bladder urothelial carcinomas. The results of our immunohistochemical analysis showed a high expression of CSE1L in bladder cancer specimens, while the normal bladder specimens only showed a very faint staining in some cells. Immunoblotting showed that CSE1L was present in urine of patients with bladder cancer. Urinary CSE1L-positive cases were detected in 95% (57/60) of patients with bladder urothelial carcinomas or the atypical/suspicious cases with urothelial atypia. No CSE1L was detected in urine of healthy controls (p<0.01). Our results suggest that urinary CSE1L deserves further evaluation for the screening of bladder cancer.

SATB1 and Her2 as predictive molecular and immunohistochemical markers for urothelial cell carcinoma of the bladder

2020 ◽  
pp. 1-11
Author(s):  
Samia Hussein ◽  
Anan Fathi ◽  
Nehal S. Abouhashem ◽  
Samar Amer ◽  
Mohamed Hemida ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Prognostic Significance ◽  
Immunohistochemical Analysis ◽  
Lymph Node Involvement ◽  
Genetic Alterations ◽  
Response To Therapy ◽  
Clinicopathological Parameters ◽  
Bladder Tissue ◽  
Normal Bladder ◽  
Erbb2 Mrna

Studying bladder cancer molecular biology revealed the presence of genetic alterations. So, detection of molecular biomarkers that help in monitoring the disease, evaluating the prognosis of the patients, and their response to therapy is needed. In this study, we investigated the expression and the prognostic significance of SATB-1 and ERBB2 mRNA and protein by quantitative RT-PCR and immunohistochemical analysis in urothelial bladder cancer cases and the surrounding normal bladder tissue. The correlations between the expression of both markers and the clinicopathological parameters were performed with further analysis of the correlation between the expression of SATB-1 and ERBB2. Compared to control, the expression of SATB-1 and ERBB2 mRNA and protein in cancer tissues were significantly up-regulated (p< 0.05). Also, a positive correlation between both markers was found (r= 0.53, p< 0.001). Moreover, elevated levels of both markers were significantly associated with the stage, lymph node involvement at both mRNA and protein levels (p< 0.001). In conclusion, there is a clinical significance of SATB-1 and ERBB2 as potential biomarkers for predicting bladder cancer patients of aggressive behavior and poor prognosis.

Urothelial Carcinomas of the Urinary Bladder With Plasmacytoid or Rhabdoid Features and Tendency of Epithelial-Mesenchymal Transition in 3 Dogs

2018 ◽  
Vol 55 (5) ◽  
pp. 673-677 ◽  
Author(s):  
Susanne Je-Han Lin ◽  
Chi-Fei Kao ◽  
Fun-In Wang ◽  
Chian-Ren Jeng ◽  
Jih-Jong Lee ◽  
...  
Keyword(s):  
Urinary Bladder ◽  
Clinical Outcome ◽  
Tumor Cells ◽  
Epithelial Mesenchymal Transition ◽  
Limited Information ◽  
Mesenchymal Transition ◽  
Invasive Behavior ◽  
Urothelial Carcinomas ◽  
Rhabdoid Features ◽  
Malignant Behavior

Plasmacytoid and rhabdoid variants of urothelial carcinomas (UCs) of the urinary bladder have been described in humans with plasma cell–like or rhabdoid cellular appearance and aggressive clinical outcome. Canine UC of the bladder is generally classified as papillary/nonpapillary and infiltrating/noninfiltrating with limited information regarding other histological patterns. We report 3 cases of UC of the urinary bladder showing a unique discohesive cellular morphology with malignant behavior resembling the human plasmacytoid and rhabdoid variants of UC, which may raise some difficulties in diagnosis. Epithelial-mesenchymal transition and reduced E-cadherin expression were revealed by immunohistochemistry in 2 cases, possibly explaining the discohesive and invasive behavior of the tumor cells. The findings broaden the morphological spectrum as well as the distinct clinical features of canine UC of the urinary bladder.

Novel oncogenic function of ATDC in bladder cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 4591-4591
Author(s):  
Phillip Lee Palmbos ◽  
Lidong Wang ◽  
Huibin Yang ◽  
Taylor Detzler ◽  
Gina Ney ◽  
...  
Keyword(s):  
Gene Expression ◽  
Bladder Cancer ◽  
Cancer Cell ◽  
Pten Expression ◽  
Cancer Tissue ◽  
Bladder Tumors ◽  
Human Bladder ◽  
Urothelial Carcinomas ◽  
Normal Bladder

4591 Background: Bladder cancer is a common and deadly disease, but the molecular events leading to its initiation and progression are incompletely understood. We recently identified Ataxia-Telangiectasia Group D Associated (ATDC) as a novel oncogene which drives tumor proliferation and invasion in pancreatic carcinoma (Cancer Cell, 2009). In this study, we describe the role of ATDC as an oncogene in bladder cancer. Methods: To further determine the oncogenic role of ATDC, we generated ATDC transgenic (tg) mice in which ATDC expression was driven by a CMV promoter and characterized the resulting tumors. Results: Interestingly, the dominant phenotype in these mice was the development of both non-invasive and invasive urothelial carcinomas (9% and 20% respectively, average age of onset 10-12 months of age). Histologically, these tumors were indistinguishable from human urothelial carcinomas. Gene expression profiling of invasive tumors derived from ATDC tg mice demonstrated a marked overlap with gene signatures of human invasive bladder cancers. ATDC was the 11th most highly up-regulated gene in bladder cancers represented in the Oncomine gene expression database. Analysis of a human bladder cancer tissue microarray (311 samples) by IHC showed elevated expression in 70% (173/252) of muscle-invasive carcinomas, 22% (5/23) of papillary tumors and little or no expression in normal bladder urothelium. ATDC tg mouse bladder tumors demonstrated loss of p53 signaling and down-regulation of PTEN expression, which correlated with ATDC induced methylation of the PTEN promoter by DNMT3A. Furthermore, ATDC knock-down in invasive cancer cell lines resulted in decreased proliferation, invasion and reactivation of p53-mediated signaling and PTEN expression. Conclusions: ATDC is a novel oncogene that is highly expressed in human bladder cancers and is sufficient to drive the development of invasive bladder tumors in tg mice. The mechanism by which ATDC drives bladder cancer formation involves alterations in p53 and PTEN pathways known to be important in bladder tumorigenesis.

ATDC as a novel oncogene in bladder cancer.

2012 ◽  
Vol 30 (5_suppl) ◽  
pp. 269-269
Author(s):  
Phillip Lee Palmbos ◽  
Lidong Wang ◽  
Huibin Yang ◽  
Taylor Detzler ◽  
Gina Ney ◽  
...  
Keyword(s):  
Gene Expression ◽  
Bladder Cancer ◽  
Cancer Cell ◽  
Pten Expression ◽  
Cancer Tissue ◽  
Bladder Tumors ◽  
Human Bladder ◽  
Urothelial Carcinomas ◽  
Normal Bladder

269 Background: Bladder cancer is a common and deadly disease, but the molecular events leading to its initiation and progression are incompletely understood. We recently identified Ataxia-Telangiectasia Group D Associated (ATDC) as a novel oncogene which drives tumor proliferation and invasion in pancreatic carcinoma (Cancer Cell, 2009). In this study, we describe the role of ATDC as an oncogene in bladder cancer. Methods: To further determine the oncogenic role of ATDC, we generated ATDC transgenic (tg) mice in which ATDC expression was driven by a CMV promoter and characterized the resulting tumors. Results: The dominant phenotype in these mice was the development of both papillary and invasive urothelial carcinomas (9% and 20% respectively, average age of onset 10-12 months of age). Histologically, these tumors were indistinguishable from human urothelial carcinomas. Gene expression profiling of invasive tumors derived from ATDC tg mice demonstrated a marked overlap with gene signatures of human invasive bladder cancers. Analysis of a human bladder cancer tissue microarray (311 samples) showed elevated expression in 70% (173/252) of muscle-invasive carcinomas, whereas normal bladder had no expression. 22% (5/23) of papillary tumors also expressed elevated levels of ATDC. ATDC was the 11th most highly up-regulated gene in bladder cancers represented in the Oncomine gene expression database. ATDC tg mouse bladder tumors demonstrated loss of p53 signaling and down-regulation of PTEN expression, which was determined to be due to ATDC abrogation of p53 function by cytoplasmic sequestration and ATDC-mediated methylation of the PTEN promoter. Furthermore, ATDC knock-down in invasive cancer cell lines resulted in decreased proliferation, invasion and reactivation of p53-mediated signaling and PTEN expression. Conclusions: ATDC is a novel oncogene that is highly expressed in human bladder cancers and is sufficient to drive the development of invasive bladder tumors in tg mice. The mechanism by which ATDC drives bladder cancer formation involves alterations in p53 and PTEN pathways known to be important in bladder tumorigenesis.

Overexpression of C1QTNF6 Predicts a Poor Prognosis in Bladder Cancer

2020 ◽  
Author(s):  
Xin Zhu ◽  
Hang Tong ◽  
Shun Gao ◽  
Hubin Yin ◽  
Gongmin Zhu ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Poor Prognosis ◽  
Clinical Characteristics ◽  
Underlying Mechanism ◽  
High Expression ◽  
Migration And Invasion ◽  
Bladder Cell ◽  
Normal Bladder ◽  
Bladder Cancer Cells ◽  
Geo Database

Abstract Background: Bladder cancer is one of the most common urinary cancer. This study aimed to provide promising molecular biomarkers for bladder cancer by investigating the correlations between C1QTNF6 expressions and clinical characteristics as well as prognosis in patients with bladder cancer.Methods: C1QTNF6 RNA sequencing profiles of bladder cancer patients were collected to evaluate different expressions between normal bladder mucosa and bladder cancer from TCGA database and GEO database. The associations between C1QTNF6 expression and clinical characteristics as well as prognosis were evaluated by two independent cohorts. The cell expression of C1QTNF6 expression between normal bladder cell and bladder cancer cells were tested in western blot and PCR, and the underlying molecular mechanism was investigated.Results: RNA levels of C1QTNF6 were found to be differentially expressed in two independent public cohorts including TCGA database and GSE13507 from GEO database. The protein and RNA expressions C1QTNF6 in bladder cell lines were both significantly elevated than normal bladder cell line. High C1QTNF6 expressions were found in advanced T status, M status, pathological grade, AJCC stage compared with low C1QTNF6 expression group. The underlying mechanism may be explained by cell migration and invasion assays that bladder cancer cells 5637 and T24 were significantly reduced migration and invasion ability with the knock-down C1QTNF6 expressions. The low RNA expression group of C1QTNF6 demonstrated OS advantage over high-expression group in both TCGA and GSE13507 cohorts. Besides, protein expressions in tissues were further validated in HPA database and TMA. Survival analysis also indicated that the high expression of C1QTNF6 indicated unfavorable OS compared with low expressions group.Conclusions: High expression of C1QTNF6 predicted poor prognosis for bladder cancer patients, and the underlying mechanism is associated with cancer cell migration and invasion ability.

scholarly journals UBC®Rapid Test for detection of carcinoma in situ for bladder cancer

Tumor Biology ◽  
2017 ◽  
Vol 39 (5) ◽  
pp. 101042831770162 ◽  
Author(s):  
Thorsten H Ecke ◽  
Sarah Weiß ◽  
Carsten Stephan ◽  
Steffen Hallmann ◽  
Dimitri Barski ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urinary Bladder ◽  
Carcinoma In Situ ◽  
Rapid Test ◽  
Control Group ◽  
Low Grade ◽  
High Grade ◽  
Healthy Controls ◽  
Muscle Invasive

UBC® Rapid Test is a test that detects fragments of cytokeratins 8 and 18 in urine. We present results of a multicentre study measuring UBC® Rapid Test in bladder cancer patients and healthy controls with focus on carcinoma in situ (CIS) and high-grade bladder cancer. From our study with N = 452 patients, we made a stratified sub-analysis for carcinoma in situ of the urinary bladder. Clinical urine samples were used from 87 patients with tumours of the urinary bladder (23 carcinoma in situ, 23 non-muscle-invasive low-grade tumours, 21 non-muscle-invasive high-grade tumours and 20 muscle-invasive high-grade tumours) and from 22 healthy controls. The cut-off value was defined at 10.0 µg/L. Urine samples were analysed by the UBC® Rapid Test point-of-care system (concile Omega 100 POC reader). Pathological levels of UBC Rapid Test in urine are higher in patients with bladder cancer in comparison to the control group (p < 0.001). Sensitivity was calculated at 86.9% for carcinoma in situ, 30.4% for non-muscle-invasive low-grade bladder cancer, 71.4% for nonmuscle-invasive high grade bladder cancer and 60% for muscle-invasive high-grade bladder cancer, and specificity was 90.9%. The area under the curve of the quantitative UBC® Rapid Test using the optimal threshold obtained by receiveroperated curve analysis was 0.75. Pathological values of UBC® Rapid Test in urine are higher in patients with high-grade bladder cancer in comparison to low-grade tumours and the healthy control group. UBC® Rapid Test has potential to be more sensitive and specific urinary protein biomarker for accurate detection of high-grade patients and could be added especially in the diagnostics for carcinoma in situ and non-muscle-invasive high-grade tumours of urinary bladder cancer.

scholarly journals Enhanced Expression of CNTD2/CCNP Predicts Poor Prognosis in Bladder Cancer Based on the GSE13507

2021 ◽  
Vol 12 ◽  
Author(s):  
Mancheng Gong ◽  
Erlin Song ◽  
Guiying Huang ◽  
Wenjun Ni ◽  
Wenjing Dong ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Patients ◽  
Cancer Progression ◽  
Poor Prognosis ◽  
Malignant Tumors ◽  
High Expression ◽  
Prognostic Indicators ◽  
Bladder Tissue ◽  
Normal Bladder ◽  
Tcga Dataset

Bladder cancer is one of the most common urogenital malignancies in the world, and there are no adequate prognostic indicators. CNTD2 is one of the atypical cyclins, which may be related to the cell cycle and even the development of cancers. Early studies have shown that CNTD2 is closely related to the occurrence and development of many malignant tumors. However, the mechanism of CNTD2 in bladder cancer has not been reported. In our research, we explored the different expressions of CNTD2 between 411 bladder cancers and 19 normal bladder tissues based on the TCGA dataset. CNTD2-related signaling pathways were identified through the GSEA. We analyzed the associations of CNTD2 expression and bladder cancer progression and survival using GSE13507. Compared with 19 cases of normal bladder tissue, CNTD2 gene expression was increased in 411 cases of bladder cancer. The high expression of CNTD2 strongly correlated with grade (P &lt; 0.0001), T classification (P = 0.0001), N classification (P = 0.00011), M classification (P = 0.044), age (P = 0.027), and gender (P = 0.0012). Bladder cancer patients with high CNTD2 expression had shorter overall survival (P &lt; 0.001). In the meantime, univariate and multivariate analyses showed that the increased expression of CNTD2 was an independent factor for poor prognosis in bladder cancer patients (P &lt; 0.001 and P &lt; 0.001, respectively). CNTD2 expression is closely related to bladder cancer progression, and the high expression of CNTD2 may be an adverse biomarker in bladder cancer patients.

scholarly journals SALL4 Expression in Urothelial Carcinoma of Urinary Bladder; a Tissue Microarray Analysis

2020 ◽  
pp. 1-3
Author(s):  
Jaudah Al-Maghrabi ◽  
◽  
Haneen Al-Maghrabi ◽  
Ahmad Ghanim ◽  
Ayman Ghanim ◽  
...  
Keyword(s):  
Urinary Bladder ◽  
Germ Cell ◽  
Urothelial Carcinoma ◽  
Regional Lymph Node ◽  
Germ Cell Tumors ◽  
Unknown Origin ◽  
High Grade ◽  
Urothelial Carcinomas ◽  
Normal Bladder ◽  
Bladder Urothelial Carcinoma

Sal-like protein 4 (SALL4) is a cellular pluripotent embryonic nuclear factor that has been a useful immunohistochemistry marker for germ-cell tumors. Our understanding of SALL4 expression in other human body malignancies remains limited. The diagnostic value of SALL4 expression as an independent diagnostic marker for patients with bladder urothelial carcinoma remains unclear. The aim of this study is to investigate the relation of SALL4 immunostaining in urinary bladder urothelial carcinoma and normal bladder urothelial tissue with clinicopathological diagnostic parameters. Material and methods: Three hundred and seventy cases of bladder urothelial carcinomas and 22 non-neoplastic bladder urothelial tissues were obtained from the Department of Pathology at King Abdulaziz University Jeddah, Saudi Arabia. Tissue microarrays were constructed. Tissue sections were stained using anti-human SALL4 monoclonal antibody. The immunostaining results were recorded and analyzed. Results: SALL4 exhibited weak nuclear expression in only 6 out of 370 cases of bladder urothelial carcinomas (1.6%). All the SALL4-positive cases were high-grade tumors. Normal urothelial tissues were all completely negative. SALL4 immunostaining revealed no association with gender, age, tumor invasiveness, stage, lymphovascular invasion, regional lymph node metastasis, or distant metastasis. Conclusion: SALL4 is rarely expressed in bladder urothelial carcinoma and is typically limited to high-grade tumors. However, this immunoexpression must be kept in mind when applying SALL4 antibody for differentiating urothelial carcinomas from germ-cell tumors and when assessing metastatic poorly differentiated tumors of unknown origin.

Sign in / Sign up

Export Citation Format

Share Document